Incident, recurrent, and procedure-requiring urolithiasis

1. SGLT2 inhibitors are associated with incident, recurrent, and procedure-requiring urolithiasis in humans (HRs 0.33–0.84; rate ratios 0.63–0.73).

   “vs. DPP-4i, SGLT2i were associated with lower incident, recurrent, and procedure-requiring stone outcomes”

   ReviewCompared with dipeptidyl peptidase-4 inhibitors in adults receiving antidiabetic pharmacotherapy

   Sodium-glucose cotransporter 2 inhibitors vs. glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors for incident and recurrent urolithiasis: a European Association of Urology Endourology systematic review

   Translational andrology and urology·Sep 23, 2026

More on SGLT2 inhibitors